Structure Therapeutics Inc. American Depositary Shares (GPCR) is a publicly traded Healthcare sector company. As of May 20, 2026, GPCR trades at $36.92 with a market cap of $2.57B and a P/E ratio of -45.88. GPCR moved +2.84% today. Year to date, GPCR is -41.26%; over the trailing twelve months it is +49.45%. Its 52-week range spans $13.22 to $94.90. Analyst consensus is strong buy with an average price target of $110.69. Rallies surfaces GPCR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Aleniglipron Achieves Over 16% Weight Loss at 44 Weeks in Phase 2 Trial: Aleniglipron delivered placebo-adjusted mean weight loss of 16.3% at 180 mg and 16.0% at 240 mg after 44 weeks in the Phase 2 ACCESS II trial, with no plateau observed. Open-label extension data showed up to 16.2% weight loss by week 56 at 120 mg and low discontinuation rates (2–3.7%).
| Metric | Value |
|---|---|
| Price | $36.92 |
| Market Cap | $2.57B |
| P/E Ratio | -45.88 |
| EPS | $-0.80 |
| Dividend Yield | 0.00% |
| 52-Week High | $94.90 |
| 52-Week Low | $13.22 |
| Volume | 1.20M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-141.20M |
| Gross Margin | 0.00% |
15 analysts cover GPCR: 0 strong buy, 15 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $110.69.